How Do We Combat Bogus Medicines in the Age of the COVID-19 Pandemic?

Wubshet Tesfaye, Solomon Abrha, Mahipal G. Sinnollareddy, Bruce Baer Arnold, Andrew Brown, Cynthia Matthew, Victor Oguoma, Gregory M. Peterson, Jackson Thomas

Research output: Contribution to journalSpecial issuepeer-review

23 Citations (Scopus)
70 Downloads (Pure)


The COVID-19 pandemic has brought concurrent challenges. The increased incidence of fake and falsified product distribution is one of these problems with tremendous impact, especially in low- and middle-income countries. Up to a tenth of medicines including antibiotics and antimalarial drugs in the African market are considered falsified. Pandemics make this worse by creating an ecosystem of confusion, distraction, and vulnerability stemming from the pandemic as health systems become more stressed and the workload of individuals increased. These environments create opportunities for substandard and falsified medicines to be more easily introduced into the marketplace by unscrupulous operators. In this work, we discussed some of the challenges with fake or falsified product distribution in the context of COVID-19 and proposed strategies to best manage this problem.
Original languageEnglish
Pages (from-to)1360-1363
Number of pages4
JournalAmerican Journal of Tropical Medicine and Hygiene
Issue number4
Publication statusPublished - 18 Aug 2020


Dive into the research topics of 'How Do We Combat Bogus Medicines in the Age of the COVID-19 Pandemic?'. Together they form a unique fingerprint.

Cite this